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Abstract
A major challenge in cancer research field is to define molecular features that distinguish cancer stem cells from normal
stem cells. In this study, we compared microRNA (miRNA) expression profiles in human glioblastoma stem cells and normal
neural stem cells using combined microarray and deep sequencing analyses. These studies allowed us to identify a set of 10
miRNAs that are considerably up-regulated or down-regulated in glioblastoma stem cells. Among them, 5 miRNAs were
further confirmed to have altered expression in three independent lines of glioblastoma stem cells by real-time RT-PCR
analysis. Moreover, two of the miRNAs with increased expression in glioblastoma stem cells also exhibited elevated
expression in glioblastoma patient tissues examined, while two miRNAs with decreased expression in glioblastoma stem
cells displayed reduced expression in tumor tissues. Furthermore, we identified two oncogenes, NRAS and PIM3, as
downstream targets of miR-124, one of the down-regulated miRNAs; and a tumor suppressor, CSMD1, as a downstream
target of miR-10a and miR-10b, two of the up-regulated miRNAs. In summary, this study led to the identification of a set of
miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. Characterizing the role of
these miRNAs in glioblastoma stem cells may lead to the development of miRNA-based therapies that specifically target
tumor stem cells, but spare normal stem cells.
Citation: Lang M-F, Yang S, Zhao C, Sun G, Murai K, et al. (2012) Genome-Wide Profiling Identified a Set of miRNAs that Are Differentially Expressed in
Glioblastoma Stem Cells and Normal Neural Stem Cells. PLoS ONE 7(4): e36248. doi:10.1371/journal.pone.0036248
Editor: Jin Q. Cheng, H.Lee Moffitt Cancer Center & Research Institute, United States of America
Received December 12, 2011; Accepted March 29, 2012; Published April 30, 2012
Copyright:  2012 Lang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH NINDS) R01 NS059546, RC1
NS068370 (http://www.ninds.nih.gov/)and California Institute for Regenerative medicine TR2-01832 (http://www.cirm.ca.gov/). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yshi@coh.org
. These authors contributed equally to this work.
Introduction
According to the World Health Organization (WHO) classifi-
cation of tumors, a grading scheme, which represents a
malignancy scale and a key factor influencing the choice of
therapies, has been successfully applied to astrocytomas, the most
common type of glioma [1]. The WHO defines pilocytic
astrocytoma as grade I, diffuse astrocytoma as grade II, anaplastic
astrocytoma as grade III, and glioblastoma as grade IV, the most
malignant grade [1]. Glioblastoma is the most common and
aggressive primary brain tumor with median survival time of 14
months after diagnosis [1]. Until now, no effective treatment has
been developed for glioblastoma patients. The goal of our research
is to identify novel molecular targets for this malignant tumor, and
thus glioblastoma is the main interest of this study. Recent studies
have led to the hypothesis that glioblastomas are maintained by a
small population of cancer stem cells that retain stem cell
properties, are highly tumorigenic, and display increased resis-
tance to radiation and chemotherapy [2–4]. These treatment-
resistant tumor cell subpopulations are the cell populations that
effective therapies must target [4].
miRNAs are short 20–22 nucleotide RNA molecules that are
expressed in a tissue-specific and developmentally-regulated
manner and function as negative regulators of gene expression
in a variety of eukaryotes. miRNAs are involved in numerous
cellular processes including development, proliferation, and
differentiation [5,6,7]. Increasing evidence has linked miRNAs
to cancer [8]. miRNAs are important regulators of many key
pathways implicated in tumor pathogenesis [9]. They can function
as either oncogenes or tumor suppressors in various tumors [10].
Recently, miRNAs have been shown to be differentially
expressed in glioblastoma tissues compared to normal brain
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36248tissues. For example, miRNA 21 is overexpressed in glioblastoma
tissues, relative to surrounding normal brain tissues [11]. miR-26a
is also amplified in glioblastoma tissues. By targeting the tumor
suppressor Pten, overexpression of miR-26a facilitates tumorigen-
esis and predicts a poor survival [12,13]. On the other hand, miR-
124, miR-137 and miR-451 exhibit reduced expression in
malignant glioblastoma tissues relative to normal brain tissues
[14,15]. The expression of these miRNAs is also reduced in
glioblastoma stem cells relative to bulk tumor cells. Overexpression
of these miRNAs in glioblastoma stem cells inhibits cell
proliferation and induces neural differentiation, suggesting a
tumor suppressor role for these miRNAs. These studies suggest
that some miRNAs may be used as therapeutic agents for targeting
glioblastoma stem cells. However, brain tumor stem cells share a
core developmental program with normal neural stem cells [10].
Optimal therapies should target tumor stem cells, but spare
normal stem cells. Therefore, identifying miRNAs that are
differentially expressed in glioblastoma stem cells and normal
neural stem cells becomes essential for the development of optimal
miRNA-based therapies for glioblastoma patients.
In this study, we present the results of a genome-wide miRNA
expression profiling in human glioblastoma stem cells and normal
neural stem cells using combined miRNA microarray and deep
sequencing analyses. This study led to the identification of eight
miRNAs that are substantially up-regulated and two miRNAs that
are significantly down-regulated in glioblastoma stem cells, relative
to normal neural stem cells. Differential expression of four of these
miRNAs, 2 up-regulated and 2 down-regulated, was further
validated by real-time RT-PCR in both glioblastoma stem cells
and glioblastoma patient tumor tissues. Moreover, we demonstrate
that these up-regulated or down-regulated miRNAs inhibit the
expression of genes that are involved in tumor suppression or
tumorigenesis, respectively.
Results
Differential miRNA expression in glioblastoma stem cells
and normal neural stem cells
In order to identify miRNAs that are differentially expressed in
glioblastoma stem cells and normal neural stem cells, we established
three primary glioblastoma stem cell lines and three normal human
neuralstemcelllinestodetermineifthereweresignificantdifferences
in miRNA expression in tumor stem cells from normal stem cells.
Human primary glioblastoma stem cells were derived from newly
diagnosed glioblastoma multiforme IV patients and cultured in
DMEM/F12 media supplemented with epithelial growth factor
(EGF), fibroblast growth factor (FGF), and B27 supplement. Human
normal neural stem cells were derived from normal human brain
tissues and cultured in the same media. Both glioblastoma stem cells
and normal neural stem cells grew as neurospheresunder the culture
condition (Fig. 1A). Both types of cells are multipotent, having the
ability to differentiate into Tuj1-positive neurons and GFAP-positive
astrocytes when induced into differentiation using fetal bovine serum
and all-trans retinoic acid (Fig. 1B). However, the glioblastoma stem
cells were able to generate tumors when transplanted to the
immunodeficient NSG mice (Fig. 1C), whereas the human neural
stem cells did not (data not shown).
Combined microarray and deep sequencing analyses were
performed to determine the expression profile of miRNAs in
glioblastoma stem cells and normal neural stem cells. Total RNAs
were prepared from both glioblastoma stem cells and neural stem
cells for miRNA microarray analysis. In microarray analysis, we
identified 10 miRNAs that are more than 5-fold up-regulated in
glioblastoma stem cells and 8 miRNAs that are more than 5-fold
down-regulated in glioblastoma stem cells, relative to neural stem
cells (Table 1). The differentially expressed miRNAs that exhibit
more than 1.5-fold difference in the expression between
glioblastoma stem cells and neural stem cells were shown in Table
S1.
Using an Illumina Genome Analyzer II (GAII) sequencing
system, we performed the whole-genome small RNA sequencing
in glioblastoma stem cells and neural stem cells. Significantly more
miRNAs were detected to be differentially expressed in glioblas-
toma stem cells and neural stem cells in deep sequencing analysis.
For example, deep sequencing analysis revealed 105 miRNAs that
were up-regulated more than 5-fold in glioblastoma stem cells.
However, microarray analysis revealed only 10 miRNAs showing
more than 5-fold increase in glioblastoma stem cells. Interestingly,
8 out of the 10 miRNAs that were up-regulated more than 5-fold
in microarray analysis also exhibited significantly increased
expression in deep sequencing analysis (Table 2). Two of the
miRNAs that had more than 5-fold decrease of expression in
microarray analysis also showed more than 5-fold reduction of
expression in deep-sequencing analysis (Table 2). Thus, combined
microarray and deep sequencing analyses allowed us to identify a
set of miRNAs that are differentially expressed in glioblastoma
stem cells and normal neural stem cells.
Validation of the differentially expressed miRNAs using
real-time RT-PCR
The distinct expression of these miRNAs in glioblastoma stem
cells and neural stem cells was further validated using real-time
RT-PCR analysis. RT-PCR results of the top three miRNAs that
are up-regulated in glioblastoma stem cells in both microarray and
deep sequencing analyses (Table 2) are shown in Fig. 2A–C. All
three miRNAs showed a significant up-regulation in the three
primary glioblastoma stem cell lines (GSC1–3) tested, compared to
three lines of normal neural stem cells. miR-10a revealed a
dramatic increase of expression in all three glioblastoma stem cell
lines tested, with more than 100-fold up-regulation of expression in
two of the glioblastoma stem cell lines (Fig. 2A). miR-10b
exhibited even higher expression in glioblastoma stem cell lines
GSC1 and GSC3, with up to 2,505-fold increase of expression in
GSC1 (Fig. 2B). miR-140-5p also displayed significant increase of
expression in all three glioblastoma stem cell lines tested, although
with much lower fold induction (Fig. 2C).
There are two miRNAs that are down-regulated more than 5-
fold in glioblastoma stem cells in both microarray and deep
sequencing analyses. The expression of these two miRNAs was
also validated using real-time RT-PCR assays. Both miR-124 and
miR-874 exhibited reproducible decrease of expression in all three
glioblastoma stem cell lines tested, compared to normal neural
stem cells (Fig. 2D, E). Specifically, the relatively new miRNA
miR-874 that has not been studied extensively exhibited a
significant reduction of expression in all three glioblastoma stem
cell lines, with more than 20-fold reduction in two of the
glioblastoma stem cell lines GSC1 and GSC3 (Fig. 2E).
In addition to cultured cells, we next tested whether the
miRNAs that are differentially expressed in glioblastoma stem cells
and neural stem cells exhibit a distinct expression pattern in
normal and glioblastoma brain tissues. For this purpose, RNAs
were isolated from 9 grade IV glioblatoma multiforme brain tissue
samples and 4 non-tumor normal brain tissue samples. Real-time
RT-PCR analyses were performed to detect the expression of two
up-regulated miRNAs and two down-regulated miRNAs. Consis-
tent with the results from tumor stem cells, miR-10a exhibited a
substantial increase of expression in most glioblastoma tissues
(Fig. 3A). miR-10b also exhibited a dramatic up-regulation of
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increase of 142-fold (Fig. 3B). For miRNAs that were down-
regulated in glioblastoma stem cells, both miR-124 and miR-874
displayed a significant decrease of expression in most of the
glioblastoma tissues tested, compared to their average expression
in normal brain tissues (Fig. 3C, D).
Target identification of the differentially-expressed
miRNAs
By using Targetscan algorithm [16], we identified CUB and
SUSHI multiple domain protein 1 (CSMD1) as a candidate target
for miR-10a and miR-10b, the most highly up-regulated miRNAs
Figure 1. The morphology, differentiation and growth curve of glioblastoma stem cells (GSCs) and neural stem cells (NSCs). A.
Representative images of neurospheres from normal human neural stem cell lines 1–3 (NSC1–3) and glioblastoma stem cell lines 1–3 (GSC1–3). B. The
multipotency of NSCs and GSCs. When induced into differentiation, both NSCs and GSCs gave rise to Tuj1+ neurons (green) and GFAP+ astrocytes
(red). Representative images of NSC1 and GSC1 differentiation were shown. Nuclear Dapi staining was shown in blue. C. H&E staining of coronal
sections from GSC-transplanted brains. The tumor region was indicated by an arrow, shown in dark purple color.
doi:10.1371/journal.pone.0036248.g001
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tumor suppressor gene that maps to chromosome 8p23, a region
deleted in many tumor types [17]. Sequence analysis revealed that
the seed region of both miR-10a and miR-10b could form
complementary base pairs with the 39 untranslated region (39
UTR) of human and mouse CSMD1 mRNAs (Fig. 4A, B). To
demonstrate a direct interaction between the 39 UTR of CSMD1
and miR-10 (miR10a and miR-10b), we inserted the 39 UTR
region of human CSMD1 that contains the putative miR-10
recognition sites and flanking sequences downstream of a Renilla
luciferase reporter gene into a siCheck vector. RNA duplexes of
mature miR-10a or miR-10b were transfected into human
embryonic kidney HEK293 cells along with the reporter gene.
Significant repression of the reporter gene was observed in both
miR-10a and miR-10b-transfected cells (Fig. 4C, D). Mutation of
the miR-10 targeting sites abolished the repression (Fig. 4C, D).
Furthermore, treatment of the inhibitors of miR-10a and miR-10b
reversed the inhibitory effect of miR-10a and miR-10b on the
luciferase reporter activity, respectively (Fig. 4C, D). These results
suggest that both miR-10a and miR-10b repress CSMD1
expression through the predicted targeting sites in CSMD1 39
UTR.
Since miR-10a and miR-10b are both up-regulated in
glioblastoma stem cells relative to neural stem cells, we next
examined the expression of CSMD1 in both cell types. Dramatic
reduction of CSMD1 mRNA expression was detected in
glioblastoma stem cells by RT-PCR analysis, compared to neural
stem cells (Fig. 4E), consistent with the observation that CSMD1
expression is repressed by miR-10 (Fig. 4C, D). The homeobox
transcription factor HOXD10 was identified as a tumor
suppressor gene targeted by miR-10b in breast cancers recently
[18]. We showed here that the HOXD10 mRNA expression is
also dramatically reduced (.20-fold) in glioblastoma stem cells
examined, compared to normal neural stem cells (Fig. 4F).
Together, these results suggest that miR-10 targets the expression
of tumor suppressor genes, CSMD1 and HOXD10, in glioblas-
toma stem cells.
Furthermore, using the Targetscan algorithm, we predicted
oncogenes NRAS and PIM3 as putative target genes of miR-124,
one of the down-regulated miRNAs in glioblastoma stem cells.
NRAS is a small guanine-nucleotide binding protein and one of
the three RAS (KRAS, NRAS, HRAS) isoforms [19]. The RAS
signaling pathway plays a crucial role in many cancers by
regulating cell proliferation, differentiation, and survival [20].
Using Targetscan algorithm, miR-124 was predicted to have a
targeting site at the 39 UTR of the NRAS gene. This targeting site
is conserved in human, mouse, and dog NRAS (Fig. 5A). To
validate the targeting of NRAS by miR-124, we made a luciferase
reporter construct with human NRAS 39 UTR containing the
predicted miR-124 targeting site and the flanking sequences
inserted into the 39UTR of a Renilla luciferase reporter gene in a
siCHECK vector. Transfection of miR-124 RNA duplexes led to
significant repression of the reporter gene (Fig. 5B). Mutation of
the putative miR-124 targeting site abolished the repression
(Fig. 5B). Furthermore, treatment with a miR-124 inhibitor
reversed the inhibitory effect of miR-124 on the luciferase reporter
activity (Fig. 5B). These results suggest that miR-124 represses
NRAS expression through the predicted targeting site in NRAS
39UTR.
Next, we tested whether miR-124 targets NRAS expression in
glioblastoma stem cells. Mature miR-124 RNA duplexes were
introduced into GSC1 cells using a cationic triethanolamine-core
polyamidoamine (PAMAM) dendrimer-mediated small RNA
delivery system [21,22]. A control RNA duplex was included as
a negative control. NRAS expression levels were examined by
Western blot analysis. Reduction of NRAS protein level was
detected in miR-124-transfected cells. Co-transfection of a miR-
124 RNA inhibitor abolished the inhibitory effect of miR-124 on
NRAS expression (Fig. 5C). This result indicates that miR-124
Table 1. Up-regulated and down-regulated miRNAs in
human glioblastoma stem cells, compared to human neural
stem cells.
miRNA
Chromosomal
location Fold-Change p-value
up-regulated
hsa-miR-10a 17q21.32 93.65 3.28E-10
hsa-miR-10b 2q31.1 90.38 2.06E-09
hsa-miR-140-3p 16q22.1 14.10 1.62E-10
hsa-miR-140-5p 16q22.1 12.19 5.56E-09
hsa-miR-204 9q21.12 9.05 4.08E-08
hsa-miR-424 Xq26.3 8.38 2.53E-08
hsa-miR-455-5p 9q32 5.87 1.48E-05
hsa-miR-455-3p 9q32 5.41 9.32E-05
down-regulated
hsa-miR-371-5p 19q13.42 215.27 8.52E-11
hsa-miR-124-1* 8p23.1 213.37 8.33E-05
hsa-miR-124-2
* 8q12.3
hsa-miR-124-3
* 20q13.33
hsa-miR-335 7q32.2 213.24 1.43E-09
hsa-miR-492 12q22 27.77 5.38E-08
hsa-miR-874 5q31.2 26.76 1.53E-08
hsa-miR-30b* 8q24.22 26.54 2.73E-09
hsa-miR-602 9q34.3 25.75 2.63E-08
*hsa-miR-124 is transcribed from three chromosomal locations, but the mature
sequences are the same.
doi:10.1371/journal.pone.0036248.t001
Table 2. The miRNA signature of glioblastoma stem cells
identified using both microarray and deep sequencing
analyses.
Microarray
Deep
sequencing
Up-regulated Fold change p value Fold change p value
hsa-miR-10a 93.65 ,1E-07 35,949 0.00E+00
hsa-miR-10b 90.38 ,1E-07 4,128 0.00E+00
hsa-miR-140-5p 12.19 ,1E-07 7.2 0.00E+00
has-miR-204 9.05 ,1E-07 5 0.00E+00
hsa-miR-424 8.38 ,1E-07 66 0.00E+00
hsa-miR-34a 7.73 2.00E-07 2.5 4.00E-240
hsa-miR-193a-3p 6.4 8.00E-06 93 9.00E-21
hsa-miR-455-5p 5.87 1.00E-05 5.3 5.00E-214
Down-regulated
hsa-miR-124 213.37 8.00E-05 210 5.00E-80
hsa-miR-874 26.76 ,1E-07 233 1.50E-98
doi:10.1371/journal.pone.0036248.t002
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stem cells.
We also examined the expression of NRAS in glioblastoma stem
cells and neural stem cells, where miR-124 exhibits differential
expression. A significant increase of NRAS mRNA expression was
detected in glioblastoma stem cells, compared to neural stem cells
(Fig. 5D). The inverse expression pattern of NRAS and miR-124 is
consistent with the observation that NRAS expression is repressed
by miR-124 (Fig. 5B, C).
A putative targeting site of miR-124 was also identified in the 39
UTR of both human and mouse PIM3, a proto-oncogene with
serine/threonine kinase activity (Fig. 5E). PIM3 has been shown to
Figure 2. Real-time RT-PCR validation of miRNA expression in glioblastoma stem cells. The expression levels of miR-10a (A), miR-10b (B),
miR-140-5p (C), miR-124 (D), and miR-874 (E) in three glioblastoma stem cell (GSC) lines were measured by real-time RT-PCR, and compared to their
expression in three neural stem cell (NSC) lines. The expression shown in each cell line is relative to the expression in NSC1, with the expression in
NSC1 as 1. Error bars are standard deviation of the mean. * p,0.001, ** p,0.005 by one way Anova test.
doi:10.1371/journal.pone.0036248.g002
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regulators [23,24]. To validate the targeting of PIM3 by miR-
124, we made a luciferase reporter construct with human PIM3 39
UTR containing the predicted miR-124 targeting site and the
flanking sequences inserted into the 39UTR of a Renilla luciferase
reporter gene. Transfection of miR-124 led to significant
repression of the reporter gene and mutation of the putative
miR-124 targeting site abolished the repression (Fig. 5F). Further-
more, treatment with a miR-124 inhibitor reversed the inhibitory
effect of miR-124 on the luciferase reporter activity (Fig. 5F).
These results suggest that miR-124 represses PIM3 expression
through the predicted targeting site in its 39 UTR.
To test whether miR-124 targets PIM3 expression in glioblas-
toma stem cells, mature miR-124 RNA duplexes were introduced
into GSC1 cells using the dendrimer-mediated delivery system
[21,22]. A control RNA duplex was included as a negative control.
Reduction of PIM3 protein level was detected in miR-124-
transfected cells by Western blot analysis. Co-transfection of a
miR-124 RNA inhibitor abolished the inhibitory effect of miR-124
on PIM3 expression (Fig. 5G). This result indicates that miR-124
down-regulates endogenous PIM3 expression in glioblastoma stem
cells. Moreover, a significant increase of PIM3 mRNA expression
was detected in the glioblastoma stem cells tested, compared to
neural stem cells (Fig. 5H), further supporting the idea that miR-
124 represses PIM3 expression.
It is increasingly clear that miRNAs are important regulators of
key signaling pathways implicated in tumorigenesis. Using Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis,
we compared the predicted targets of miRNAs that showed more
than 5-fold up-regulation or down-regulation in glioblastoma stem
cells in our microarray analysis. Seven of the ten miRNAs that
were up-regulated more than 5-fold in glioblastoma stem cells are
predicted to have components of the p53 pathway as common
targets (Fig. 6A). The p53 pathway has been shown to be involved
in cell cycle arrest, apoptosis, inhibition of cell migration,
inhibition of angiogenesis, and affect genomic stability [25]. In
contrast, five out of eight miRNAs that exhibited more than 5-fold
down-regulation in glioblastoma stem cells were predicted to
target components of the IGF pathway (Fig. 6B) that has been
implicated in promoting cell growth, survival and migration [26].
Discussion
In the present study, we investigated genome-wide miRNA
expression in tumor stem cell populations of glioblastoma, the
most frequent and malignant primary brain tumor. In spite of
recent improvement of surgical and radiotherapeutic techniques,
the prognosis for glioblastoma patients is still very poor. The
search for molecular targets is fundamental to develop effective
treatments for glioblastoma.
Global profiling is one of the most effective approaches to
identify abnormally expressed miRNAs in tumor genomes. In this
study, we used three different technical platforms to determine the
differential expression of miRNAs in glioblastoma stem cells and
Figure 3. Real-time RT-PCR analysis of miRNA expression in glioblastoma tissues. The expression levels of miR-10a (A), miR-10b (B), miR-
124 (C), and miR-874 (D) in 9 glioblastoma tissues and 4 normal brain tissues were determine by real-time RT-PCR analysis, shown in scatted graph
and bar graph. Error bars are standard error of the mean. p value was obtained by student’s t-test.
doi:10.1371/journal.pone.0036248.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e36248Figure 4. Expression of miR-10b targets in glioblastoma stem cells. A, B. The base-pairing of hsa-miR-10a and hsa-miR-10b with the 39 UTR
of CSMD1 gene. C. miR-10a-mediated repression of luciferase reporter gene downstream of 39 UTR of CSMD1. Luciferase reporter gene under the
control of wild type (WT) or mutant (MT) CSMD1 39 UTR was transfected into HEK 293 cells along with control, miR-10a RNA duplexes, or the
combination of miR-10a RNA duplexes and a miR-10a inhibitor. * p,0.001 by student’s t-test. D. miR-10b-mediated repression of luciferase reporter
MicroRNA Signature of Glioblastoma Stem Cells
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newly emerged small RNA deep sequencing technology to profile
miRNA expression in glioblastoma stem cells and normal neural
stem cells and validated the profiling results using quantitative RT-
PCR. Although the absolute fold change obtained from each
platform is different due to the different sensitivity of the
techniques, the trend of the change for the miRNAs studied is
consistent. The miRNA expression profile could clearly distinguish
glioblastoma stem cells from normal neural stem cells, allowing us
to identify a miRNA signature of glioblastoma stem cells that were
significantly up-regulated or down-regulated in glioblastoma stem
cells, relative to neural stem cells.
In line with our findings that a set of miRNAs are differentially
expressed in glioblastoma stem cells and normal neural stem cells,
certain miRNAs also exhibit distinct expression profiles in
glioblastoma tissues and normal brain tissues. For example, we
demonstrate for the first time in this study that the expression of
miR-874 is dramatically reduced in glioblastoma tissues, com-
pared to normal brain tissues. miR-124, another miRNA that was
down-regulated in glioblastoma stem cells, also exhibited reduced
expression in glioblastoma tissues in this study, consistent with the
results of previous glioblastoma tumor tissue profiling [12,14,27–
31].
In this study, we show that miR-10b is highly expressed in both
glioblastoma stem cells and in glioblastoma tumor tissues. Up-
regulation of miR-10b was also observed in other glioblastoma
samples [12,27,28], suggesting an important role for miR-10b in
glioblastoma tumorigenesis. Moreover, a recent study revealed
that miR-10b expression is inversely correlated with glioblastoma
patient survival [32]. Interestingly, miR-10b was also found to be
up-regulated in breast cancer, leukemia, and pancreatic cancer
and promote tumor invasion and metastasis in breast cancer
[18,33,34]. Together, these results suggest that some miRNAs,
such as miR-10b, may function as a global oncogene to stimulate
tumorigenesis in multiple tissues. Likewise, miR-124 is also
frequently down-regulated in other cancers, such as medulloblas-
toma, hepatocellular carcinoma, and oral squamous carcinoma
[35–37], suggesting that it may function as a general tumor
suppressor. Therefore the knowledge of miRNAs that we have
obtained for glioblastoma stem cells may shed lights to other
cancer stem cells.
Pathway analysis revealed that most of the significantly up-
regulated miRNAs, with more than 5-fold increase in glioblastoma
stem cells as shown in our microarray analysis, have putative
targets in a common pathway, the p53 pathway. The dysregula-
tion of the p53 pathway has been shown to be an underlying
mechanism for tumorigenesis [25], thus the up-regulated miRNAs
may function as oncomiRs by targeting the p53 pathway if their
role in regulating the p53 pathway is confirmed. On the other
hand, most of the down-regulated miRNAs, with more than 5-fold
decrease in glioblastoma stem cells, share their predicted targets in
the IGF signaling. Repression of the IGF signaling has been shown
to inhibit tumorigenesis [26]. Thus, these down-regulated
miRNAs may assume a role of tumor suppressors by targeting
components of the IGF pathway if their role in regulating the IGF
signaling is confirmed. The identification of miRNAs as oncogenes
or tumor suppressors holds the promise of identifying novel
diagnostic markers or molecular targets for antitumor therapies.
The prediction that the differentially expressed miRNAs have the
ability to target multiple components in one or more pathways
makes them potential molecular targets for cancer therapy.
Glioblastoma stem cells represent a subpopulation of cancer
cells with extraordinary capacities to promote tumor growth,
invasion and therapeutic resistance, making them an ideal target
cell population for anti-glioblastoma therapies. However, a major
challenge is to define functional and molecular features that can
distinguish cancer stem cells from normal stem cells in order to
develop therapeutic strategies that specifically target the tumor
population, but leave normal stem cells intact. Therefore
comparing miRNA expression between glioblastoma stem cells
and normal neural stem cells is highly relevant in that it may lead
to the identification of glioblastoma stem cell-specific miRNAs,
thus resulting in the development of novel glioblastoma therapies
by targeting only tumor stem cells. We performed the comparison
of miRNA expression between glioblastoma stem cells from adult
glioblastoma patients and normal neural stem cells from human
fetal brains instead of human adult brains due to the inaccessibility
of normal human adult brain tissues containing neural stem cells.
Although differences do exist between embryonic neural stem cells
and adult neural stem cells, it has been proposed that embryonic
neural stem cells resemble adult neural stem cells in many ways
[38]. Therefore this comparison will provide useful information
regarding glioblastoma stem cell-specific miRNA expression and
provide a basis for strategic targeting glioblastoma stem cells
through modulation of tumor stem cell-specific miRNA expres-
sion.
miRNAs have been shown to be involved in tumor initiation
and progression, functioning as oncogenes or tumor suppressor
[9,10]. Therefore, modulation of miRNA expression provides
great hope for potential cancer therapy [39]. Furthermore, since
each miRNA may have more than one targets, miRNA-based
gene therapy offers the therapeutic appeal of targeting multiple
gene networks that are controlled by a single miRNA [9].
Strategies for miRNA-based cancer therapy include overexpres-
sion of tumor suppressor miRNAs and targeting oncogenic
miRNAs using their antagonists. Based on the miRNA signature
that we have identified in glioblastoma stem cells, we may be able
to develop targeted glioblastoma therapies by inhibiting the up-
regulated miR-10a or miR-10b function using miR-10 antogonists
or overexpressing the down-regulated miR-124 or miR-874. Of
note,16 miRNAs that are up-regulated in glioblastoma stem cells
(.1.5-fold, Table S1) in our study, including miR-10a and miR-
10b, are also up-regulated in malignant astrocytomas (glioblasto-
mas and anaplastic astrocytomas) in a genome-wide miRNA
expression profiling between malignant astrocytomas and normal
brain samples [40]. Eleven miRNAs that are down-regulated in
glioblastoma stem cells (.1.5-fold, Table S1) in our study,
including miR-124, are also down-regulated in malignant
astrocytomas.
Moreover, the prognosis of glioblastoma patients remains poor.
Biomarkers for this disease are needed for early detection of tumor
progression [41]. The miRNA signature that we identified here
may be used as biomarkers to differentiate glioblastoma stem cells
from normal neural stem cells. Recently, a miRNA signature was
gene downstream of 39 UTR of CSMD1. WT or MT CSMD1 39 UTR luciferase reporter was transfected into HEK 293 cells along with control, miR-10b
RNA duplexes, or the combination of miR-10b RNA duplexes and a miR-10b inhibitor. * p,0.005 by student’s t-test. E. Expression of CSMD1 in
glioblastoma stem cell line 1 (GSC) and neural stem cell line 1 (NSC) determined by real-time RT-PCR analysis. F. Expression of HOXD10 in GSC and
NSC determined by real-time RT-PCR analysis. For all panels, data shown are mean 6 standard deviation of three replicates. ** p,0.01 by student’s t-
test for both panels E and F.
doi:10.1371/journal.pone.0036248.g004
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36248Figure 5. miR-124 targets NRAS and PIM3 expression. A. The base-pairing of hsa-miR-124 with the 39 UTR of NRAS gene. B. miR-124-mediated
repression of luciferase reporter gene downstream of 39 UTR of NRAS. Luciferase reporter gene under the control of wild type (WT) or mutant (MT)
NRAS 39 UTR was transfected into HEK 293 cells along with control, miR-124 RNA duplexes, or the combination of miR-124 RNA duplexes and a miR-
124 inhibitor. *p,0.001 by student’s t-test. C. Western blot analysis of NRAS expression in control RNA, miR-124 RNA duplexes, or the combination of
miR-124 RNA duplexes and a miR-124 inhibitor-transfected GSC1 cells. D. Expression of NRAS in GSC1 and NSC1 determined by real-time RT-PCR
analysis. *p,0.05 by student’s t-test. E. The base-pairing of hsa-miR-124 with the 39 UTR of PIM3 gene. F. miR-124-mediated repression of luciferase
reporter gene downstream of 39 UTR of PIM3. Luciferase reporter gene under the control of wild type (WT) or mutant (MT) PIM3 39 UTR was
transfected into HEK 293 cells along with control, miR-124 RNA duplexes, or the combination of miR-124 RNA duplexes and a miR-124 inhibitor.
*p,0.001 by student’s t-test. G. Western blot analysis of PIM3 expression in control RNA, miR-124 RNA duplexes, or the combination of miR-124 RNA
duplexes and a miR-124 inhibitor-transfected GSC1 cells. H. Expression of PIM3 in GSC1 and NSC1 determined by real-time RT-PCR analysis.
**p,0.001 by student’s t-test. For all panels, data shown are mean 6 standard deviation of three replicates.
doi:10.1371/journal.pone.0036248.g005
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Interestingly, several of the miRNAs that showed elevated
expression in the blood samples of glioblastoma patients (vs
healthy control) also exhibited increased expression in glioblasto-
ma stem cells (vs normal neural stem cells) in our study (Table S1),
including miR-424, miR-148a, miR-362-3p, miR-30d, miR-128.
These miRNAs may therefore represent easily accessible bio-
markers that can be used for diagnostic purposes in glioblastoma
patients.
Materials and Methods
Ethics statement
The derivation of PBT003 (GSC1) and PBT017 (GSC2) has
been described by Brown et al [42]. PBT707 (GSC3) is a de novo
cell line derived from anonymized leftover tissues with the
approval of the City of Hope Institutional Review Board. The
study involves the use of completely anonymized specimens. No
informed consent is involved. NOD-scid IL2Rgamma
null (NSG)
mice (6–8weeks) were used for glioblastoma stem cell transplan-
tation. Tumor cell transplantation was performed under the
Figure 6. Pathways targeted by deregulated miRNAs in glioblastoma stem cells. Common miRNA targets were subjected to DAVID
functional annotation with KEGG pathway analysis. A. The up-regulated miRNAs in glioblastoma stem cells were predicted to target the p53
pathway. The p53-centered pathway has been shown to regulate cell cycle, apoptosis, angiogenesis, metastasis, and genome stability. B. The down-
regulated miRNAs were predicted to target components of the IGF pathway. Various components of the IGF signaling pathways were targeted by
down-regulated miRNAs. The IGF pathway has been shown to enhance cell growth, survival, and migration.
doi:10.1371/journal.pone.0036248.g006
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Institutional Animal Care and Use Committee.
Glioblastoma stem cell and neural stem cell culture
Glioblastoma stem cells were derived from newly diagnosed
WHO grade IV glioblastoma tissues. Specifically, freshly isolated
glioblastoma tissues were minced with sterile scissors and
dissociated into single cells using 400 units/ml of collagenase III
in DMEM/F12 medium supplemented with 5 mg/ml heparin, 16
B27 (GIBCO/BRL), and 2 mM L-glutamine. Dissociated cells
were then centrifuged at 1,200 rpm for 5 min and the supernatant
was discarded. To eliminate red blood cells, the resultant cells
were incubated in 10 ml red blood cell lysis buffer (Invitrogen) for
10 min. Cells were centrifuged again at 1,200 rpm for 5 min and
supernatant was discarded. The resultant cells were resuspended
in DMEM/F12 medium supplemented with 20 ng/ml EGF,
20 ng/ml FGF, 5 mg/ml heparin, 16 B27 (GIBCO/BRL), and
2 mM L-glutamine and cultured in this medium thereafter.
Tumor spheres appeared around one week in culture. Normal
human neural stem cells were derived from primary human brain
tissues and maintained in the same culture media. Specifically,
human fetal brain tissues (Biosciences Resources) were dissociated
in cold Hanks balance salt solution (HBSS) using polished glass
pipette. The resultant cells were centrifuged and resuspended in
DMEM/F12 medium supplemented with 0.56 B27, 25 mg/ml
insulin, 20 mg/ml apo-transferrin, 30 nM sodium selenite, 20 nM
progesterone, 100 mM putrescine, 20 ng/ml FGF and 10 ng/ml
LIF. The initial culture was split at 1:2 each day for 4 days,
followed by media change every other day till day 21. Human
neurospheres started to appear around day 14. The spheres were
split around day 21 with Accutase (Sigma) and cultured in
DMEM/F12 medium supplemented with 20 ng/ml EGF, 20 ng/
ml FGF, 5 mg/ml heparin, 16B27 (GIBCO/BRL), and 2 mM L-
glutamine thereafter. Both tumor spheres and normal neuro-
spheres were characterized for their self-renewal and multi-
potency. Glioblastoma stem cell spheres were also characterized
for their ability to derive brain tumors.
For differentiation, both glioblastoma stem cells and neural stem
cells were induced into differentiation using 0.5% fetal bovine
serum and 1 mM all-trans retinoic acid. For in vivo tumor
formation assays, 2610
5 dissociated glioblastoma stem cells were
injected into cerebral cortex of NSG mice by stereotaxic injection.
The coordinates for the injection were AP 0.6 mm, ML +1.6 mm
and DV 22.6 mm. Brains were harvested 5 weeks after cell
transplantation. Frozen brains were cut into 20 mm coronal
sections, followed by Hematoxylin & Eosin (H&E) staining.
Glioblastoma stem cell transfection using a dendrimer-
based delivery system
Spheres of glioblastoma stem cells were dissociated and seeded
into 24-well plates at 2610
5 cells per well in 300 ml of medium.
The generation-5 (G5) dendrimers and Opti-MEM solution were
mixed by vortex for 10 seconds, and incubated at room
temperature (RT) for 10 min. The miRNA duplexes or the
combination of miRNAs and their short hairpin RNA inhibitors
were added into dendrimer/Opti-MEM solution in a total volume
of 100 ml, mixed gently for 10 sec, and incubated at RT for
25 min. The nitrogen-to-phosphorus (N/P) ratio of the dendri-
mer/RNA complex is 5. The 100 ml dendrimer/RNA complex
was added into 300 ml cell suspension in each well of 24-well
plates, shake gently and put back to CO2 incubator. Forty-eight hr
after transfection, cells were collected and subjected to Western
blot analysis.
Western blot analysis
Whole cell extracts of glioblastoma stem cells were prepared
using RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1%
NP40, 0.5% deoxycholate and 0.1% SDS) containing protease
inhibitor cocktail (Roche). Western blotting was performed with
anti-NRAS (sc-31, 1:100) and anti-PIM3 (sc-98959, 1:100)
antibodies from Santa Cruz.
Glioblastoma stem cell transplantation
NSG mice (6–8weeks) were used for glioblastoma stem cell
transplantation. Tumor cell transplantation was performed under
the IACUC protocol 05050 approved by the City of Hope
Institutional Animal Care and Use Committee. 5610
4 dissociated
glioblastoma stem cells were injected into the front lobe of
forebrains by stereotaxic injection. The coordinates for the
injection were AP 0.6 mm, ML +1.6 mm and DV 22.6 mm.
Reporter construct preparation
DNA fragments encoding the 39 UTR of putative miRNA
targets were cloned into psiCHECK 2 (Promega), downstream of a
Renilla luciferase reporter gene. The PCR primers that were used
for 39 UTR cloning of each gene are as follows: CSMD1 forward:
59 GAT CCT CGA GCT GTT CTG TCG CAG AAT G 39 and
CSMD1 reverse: 59 GAT CGC GGC CGC GTC AGC ATT
TTG CAC CTA G39; PIM3 forward: 59 GAT CCT CGA GGC
TTG TGA GGA GCT GCA C 39 and PIM3 reverse: 59 GAT
CGC GGC CGC GGA AAC TTG TCA GGT CAC C 39; NRAS
forward: 59 GAT CCT CGA GCT GGA GGA GAA GTA TTC
CTG 39 and NRAS reverse: 59 GAT CGC GGC CGC TGC
AAA TGT AGA GCT TTC TGG 39. Corresponding miRNA
binding sites on the 39 UTRs were mutated by site-directed
mutagenesis according to the manufacturer’s instructions (Strata-
gene). The binding site of hsa-miR-124 on the 39 UTR of PIM3
and NRAS was mutated from GTGCCTT to GTGGACA; the
binding site of hsa-miR-10b on the 39 UTR of CSMD1 was
mutated from ACAGGGT to ACAGTCC.
Transfection and reporter assay
We transfected plasmid DNA or DNA-miRNA mixture into
HEK293 cells using Transfectin (Bio-Rad) as described [43–45].
miR-10a, miR-10b or miR-124 RNA duplexes and/ or their
correspondent RNA inhibitors (Dharmacon) were mixed in 50 ml
serum free media with Transfectin, incubated at RT for 20 min.
Negative controls for miRNA and their hairpin inhibitors were
included. The final concentration of miRNAs or their inhibitors
was 20 nM. The resultant mixture was added dropwise to
HEK293 cells in a 24-well plate with 450 ml medium per well to
a total volume of 500 ml per well. The transfected cells were
harvested 48 h after transfection and subjected to subsequent
reporter assays as described [46]. Reporter Renilla luciferase
activity was measured 48 hrs after transfection using Dual
Luciferase Assay kit (Promega). The Renilla luciferase activity was
normalized by firefly luciferase internal control and expressed as
relative luciferase activity. The miR-10a RNA duplex sense
sequence is 59 TAC CCT GTA GAT CCG AAT TTG TG 39.
The miR-10b RNA duplex sense sequence is 59 TAC CCT GTA
GAA CCG AAT TTG TG 39. The miR-124 RNA duplex sense
sequence is 59 TAA GGC ACG CGG TGA ATG CC 39. And the
control RNA duplex sense sequence is 59 UCA CAA CCU CCU
AGA AAG AGU AGA 39.
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For miRNA expression, total RNAs were reversely transcribed
and quantified by real-time RT-PCR with TaqMan MicroRNA
Assay kit (Applied Biosystems). The expression of specific miRNAs
was normalized using human U18 snRNA. For mRNA expres-
sion, putative miRNA targets were quantified by iTaq SYBR
Green Supermix with ROX (Bio-Rad). Primers used for RT-PCR
include PIM3 forward: 59 AGC TCA AGC TCA TCG ACT TC
39 and PIM3 reverse: 59 TAG CGG TGG TAG CGG ATC 39;
NRAS forward: 59 CCA TGA GAG ACC AAT ACA TGA G 39
and NRAS reverse: 59 GCT TAA TCT GCT CCC TGT AG 39;
HOXD10 forward: 59 TTC CCG AAG AGA GGA GCT G 39
and HOXD10 reverse: 59 CTG CCA CTC TTT GCA GTG AG
39; CSMD1 forward: 59 GCA GAA ATG CTT ACT GAG GAT
G3 9 and CSMD1 reverse: 59 AGA ACC CTC AAA CTG CAA
CTG 39; GAPDH forward: 59 ATC ACC ATC TTC CAG GAG
C3 9 and GAPDH reverse 59 CCT TCT CCA TGG TGG TGA
AG 39.
miRNA microarray and deep sequencing analysis
Total RNAs were extracted from glioblastoma stem cells or
human neural stem cells by TRIzol (Invitrogen) method according
to manufacturer’s protocol. Ten mg of RNA was used for miRNA
microarray using Exiqon platform. One mg of RNA was used for
deep sequencing using Illumina Genome Analyser II (GAII). All
data are MIAME compliant.
Pathway analysis
Common putative targets of either the down-regulated or the
up-regulated miRNAs were uploaded onto the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
Functional Annotation Bioinformatics Microarray Analysis
(http://david.abcc.ncifcrf.gov/). Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway in DAVID was used to depict the
biological meanings of the common miRNA targets.
Supporting Information
Table S1 Up-regulated and down-regulated miRNAs
(.1.5 fold) in human glioblastoma stem cells, compared
to human neural stem cells.
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